Fox Run Management, L.L.C. Lantheus Holdings, Inc. Transaction History

Fox Run Management, L.L.C.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$58.87 - $83.05 $591,820 - $834,901	-10,053 Reduced 56.89%	7,619 $611,000
Q1 2024 May 13, 2024	BUY	$51.07 - $68.26 $902,509 - $1.21 Million	17,672 New	17,672 $1.1 Million
Q2 2023 Aug 11, 2023	BUY	$82.41 - $99.65 $855,168 - $1.03 Million	10,377 New	10,377 $870,000
Q4 2022 Feb 07, 2023	SELL	$48.76 - $77.67 $192,309 - $306,330	-3,944 Reduced 46.87%	4,470 $227,000
Q3 2022 Nov 07, 2022	BUY	$61.42 - $86.29 $516,787 - $726,044	8,414 New	8,414 $592,000
Q2 2022 Aug 12, 2022	SELL	$55.54 - $72.65 $476,866 - $623,772	-8,586 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$24.28 - $56.64 $208,468 - $486,311	8,586 New	8,586 $475,000
Q3 2021 Nov 15, 2021	SELL	$24.23 - $28.59 $375,758 - $443,373	-15,508 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$19.51 - $27.64 $302,561 - $428,641	15,508 New	15,508 $429,000
Q1 2018 Apr 17, 2018	SELL	$14.85 - $24.3 $349,435 - $571,803	-23,531 Closed	0 $0
Q4 2017 Jan 18, 2018	BUY	$17.4 - $23.4 $409,439 - $550,625	23,531	23,531 $481,000

540

68M

679K

423K

Ticker LNTH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 68,741,904
Market Cap $6.1B
Description
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for n...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.